Anne-Marie Connolly-Andersen1, Erik Sundberg2, Clas Ahlm1, Johan Hultdin3, Maria Baudin1, Johanna Larsson3, Eimear Dunne4, Dermot Kenny4, Tomas L Lindahl5, Sofia Ramström5, Sofie Nilsson3. 1. Infectious Diseases, Department of Clinical Microbiology. 2. Infectious Diseases, Department of Clinical Microbiology Clinical Chemistry, Department of Medical Biosciences, Umeå University, Sweden. 3. Clinical Chemistry, Department of Medical Biosciences, Umeå University, Sweden. 4. Clinical Research Centre, Royal College of Surgeons in Ireland, Dublin. 5. Department of Clinical and Experimental Medicine, Linköping University, Sweden.
Abstract
BACKGROUND: Thrombocytopenia is a common finding during viral hemorrhagic fever, which includes hemorrhagic fever with renal syndrome (HFRS). The 2 main causes for thrombocytopenia are impaired thrombopoiesis and/or increased peripheral destruction of platelets. In addition, there is an increased intravascular coagulation risk during HFRS, which could be due to platelet activation. METHODS: Thrombopoiesis was determined by quantification of platelet counts, thrombopoietin, immature platelet fraction, and mean platelet volume during HFRS. The in vivo platelet activation was determined by quantification of soluble P-selectin (sP-selectin) and glycoprotein VI (sGPVI). The function of circulating platelets was determined by ex vivo stimulation followed by flow cytometry analysis of platelet surface-bound fibrinogen and P-selectin exposure. Intravascular coagulation during disease was determined by scoring for disseminated intravascular coagulation (DIC) and recording thromboembolic complications. RESULTS: The levels of thrombopoietin, immature platelet fraction, and mean platelet volume all indicate increased thrombopoiesis during HFRS. Circulating platelets had reduced ex vivo function during disease compared to follow-up. Most interestingly, we observed significantly increased in vivo platelet activation in HFRS patients with intravascular coagulation (DIC and thromboembolic complications) as shown by sP-selectin and sGPVI levels. CONCLUSIONS: HFRS patients have increased thrombopoiesis and platelet activation, which contributes to intravascular coagulation.
BACKGROUND:Thrombocytopenia is a common finding during viral hemorrhagic fever, which includes hemorrhagic fever with renal syndrome (HFRS). The 2 main causes for thrombocytopenia are impaired thrombopoiesis and/or increased peripheral destruction of platelets. In addition, there is an increased intravascular coagulation risk during HFRS, which could be due to platelet activation. METHODS: Thrombopoiesis was determined by quantification of platelet counts, thrombopoietin, immature platelet fraction, and mean platelet volume during HFRS. The in vivo platelet activation was determined by quantification of soluble P-selectin (sP-selectin) and glycoprotein VI (sGPVI). The function of circulating platelets was determined by ex vivo stimulation followed by flow cytometry analysis of platelet surface-bound fibrinogen and P-selectin exposure. Intravascular coagulation during disease was determined by scoring for disseminated intravascular coagulation (DIC) and recording thromboembolic complications. RESULTS: The levels of thrombopoietin, immature platelet fraction, and mean platelet volume all indicate increased thrombopoiesis during HFRS. Circulating platelets had reduced ex vivo function during disease compared to follow-up. Most interestingly, we observed significantly increased in vivo platelet activation in HFRSpatients with intravascular coagulation (DIC and thromboembolic complications) as shown by sP-selectin and sGPVI levels. CONCLUSIONS:HFRSpatients have increased thrombopoiesis and platelet activation, which contributes to intravascular coagulation.
Authors: Felix C Koehler; Veronica Di Cristanziano; Martin R Späth; K Johanna R Hoyer-Allo; Manuel Wanken; Roman-Ulrich Müller; Volker Burst Journal: Clin Kidney J Date: 2022-01-29
Authors: Svetlana F Khaiboullina; Sergey P Morzunov; Stephen C St Jeor; Albert A Rizvanov; Vincent C Lombardi Journal: Front Microbiol Date: 2016-07-19 Impact factor: 5.640
Authors: Ekaterina V Martynova; Aygul H Valiullina; Oleg A Gusev; Yuriy N Davidyuk; Ekaterina E Garanina; Venera G Shakirova; Ilsiyar Khaertynova; Vladimir A Anokhin; Albert A Rizvanov; Svetlana F Khaiboullina Journal: J Immunol Res Date: 2016-12-05 Impact factor: 4.818
Authors: John R Stack; Anne Madigan; Laura Helbert; Eimear Dunne; Elizabeth E Gardiner; Robert K Andrews; Roisin Finan; Elizabeth Smyth; Dermot Kenny; Geraldine M McCarthy Journal: PLoS One Date: 2017-11-15 Impact factor: 3.240
Authors: Sirpa Koskela; Outi Laine; Satu Mäkelä; Tanja Pessi; Sari Tuomisto; Heini Huhtala; Pekka J Karhunen; Ilkka Pörsti; Jukka Mustonen Journal: PLoS One Date: 2015-11-11 Impact factor: 3.240
Authors: Priscilla F Kerkman; Andy Dernstedt; Lalitha Tadala; Eva Mittler; Mirjam Dannborg; Christopher Sundling; Kimia T Maleki; Johanna Tauriainen; Anne Tuiskunen-Bäck; Julia Wigren Byström; Pauline Ocaya; Therese Thunberg; Rohit K Jangra; Gleyder Román-Sosa; Pablo Guardado-Calvo; Felix A Rey; Jonas Klingström; Kartik Chandran; Andrea Puhar; Clas Ahlm; Mattias Ne Forsell Journal: Clin Transl Immunology Date: 2021-07-12